PBS recommendations for NSCLC, melanoma drugs and ondansetron

The Pharmaceutical Benefits Advisory Committee has recommended PBS listings for entrectinib in NSCLC, pembrolizumab in melanoma and ondansetron for chemotherapy-related nauseas and vomiting At its March meeting the PBAC recommended the listing of entrectinib as monotherapy for the treatment of patients with locally advanced (Stage IIIB) or metastatic (Stage IV) ROS1-positive non-squamous or not otherwise ...

Already a member?

Login to keep reading.

© 2022 the limbic